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ABSTRACT
Fetal valproate syndrome (FVS) is caused by in utero exposure to the
drug sodium valproate. Valproate is used worldwide for the treatment
of epilepsy, as a mood stabiliser and for its pain-relieving properties.
In addition to birth defects, FVS is associated with an increased risk
of autism spectrum disorder (ASD), which is characterised by
abnormal behaviours. Valproate perturbs multiple biochemical
pathways and alters gene expression through its inhibition of histone
deacetylases. Which, if any, of these mechanisms is relevant to the
genesis of its behavioural side effects is unclear. Neuroanatomical
changes associated with FVS have been reported and, among these,
altered serotonergic neuronal differentiation is a consistent finding.
Altered serotonin homeostasis is also associated with autism. Here
we have used a chemical-genetics approach to investigate the
underlying molecular defect in a zebrafish FVS model. Valproate
causes the selective failure of zebrafish central serotonin expression.
It does so by downregulating the proneural gene ascl1b, an ortholog
of mammalian Ascl1, which is a known determinant of serotonergic
identity in the mammalian brainstem. ascl1b is sufficient to rescue
serotonin expression in valproate-treated embryos. Chemical and
genetic blockade of the histone deacetylase Hdac1 downregulates
ascl1b, consistent with the Hdac1-mediated silencing of ascl1b
expression by valproate. Moreover, tonic Notch signalling is crucial for
ascl1b repression by valproate. Concomitant blockade of Notch
signalling restores ascl1b expression and serotonin expression in both
valproate-exposed and hdac1 mutant embryos. Together, these data
provide a molecular explanation for serotonergic defects in FVS and
highlight an epigenetic mechanism for genome-environment
interaction in disease.
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INTRODUCTION
Valproate (VPA) is a fatty acid derivative widely prescribed for its
anticonvulsant, mood-stabilising and pain-relieving properties, but
it has teratogenic and neuropsychiatric side effects upon in utero
exposure, collectively termed fetal valproate syndrome (FVS). The
underlying molecular cause of FVS is unknown, but candidate
mechanisms are the dysregulation of transcription factors important
for brain development, disruption of signal transduction pathways,
inositol depletion and direct inhibition of epigenetic regulators such
as the histone deacetylases (HDACs) (Chen et al., 1997; Detich et
al., 2003; Einat et al., 2003; Marchion et al., 2005; Milutinovic et
al., 2007; Phiel et al., 2001; Williams et al., 2002).
Fetal VPA exposure is associated with a 3- to 46-fold increased
risk of autism spectrum disorder (ASD) (Bromley et al., 2013;
Christensen et al., 2013; Dufour-Rainfray et al., 2011; Rasalam et
al., 2005). Animal models of FVS display autism-like behaviours
(Dufour-Rainfray et al., 2010; Kim et al., 2011; Yochum et al., 2008)
and neuroanatomical abnormalities that are also reported in ASD
(Ingram et al., 2000; Rodier et al., 1996). In these models, activity
of the neurotransmitter serotonin (5HT) is altered, which has been
implicated in the regulation of numerous behaviours, including
social interaction (Ansorge et al., 2004; Patterson, 2006). Altered
hippocampal and blood 5HT levels have been reported in animal
models of FVS, which correlate with impaired 5HT neuronal
differentiation (Dufour-Rainfray et al., 2010; Kuwagata et al., 2009;
Miyazaki et al., 2005; Narita et al., 2002; Oyabu et al., 2013) and
autism-like behaviours (Lin et al., 2013; Tsujino et al., 2007; Wang
et al., 2013). Interestingly, in one of these rat models, treatment with
a 5HT1A receptor agonist improved the abnormal behaviours,
implying a deficit of 5HT signalling (Wang et al., 2013). By
contrast, in the other study, VPA increased brain 5HT levels (Tsujino
et al., 2007).
Significantly, 5HT is also implicated in autism pathogenesis. In
ASD, 30% of subjects have elevated 5HT blood levels (Mulder et
al., 2004; Schain and Freedman, 1961), central 5HT homeostasis is
altered (Chugani et al., 1999; Chugani et al., 1997) and an
association with stereotyped behaviour has been reported (Kolevzon
et al., 2010; Sacco et al., 2010). Selective serotonin reuptake
inhibitors (SSRIs) improve some manifestations of autism, including
stereotypical behaviours (Hollander et al., 2003; McDougle et al.,
2000), whereas depletion of the 5HT precursor tryptophan
exacerbates these symptoms (Bauman et al., 2006). Genetic or
pharmacological perturbation of the 5HT system is associated with
autism-like behaviours in humans and in rodents (Bauman et al.,
2006; Cook et al., 1997; Kane et al., 2012; Klauck et al., 1997; Nabi
et al., 2004; Nakatani et al., 2009; Sutcliffe et al., 2005; Veenstra-
VanderWeele et al., 2012). In particular, an allelic polymorphism of
the serotonin transporter gene (SERT), which is a determinant of
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5HT activity, is associated with ASD (Devlin et al., 2005).
Furthermore, a mouse model of one of the human gain-of-function
SERT genetic variants displays ASD-like behaviours and
hyperserotonaemia (Veenstra-VanderWeele et al., 2012). Therefore,
increases and decreases in central 5HT activity seem to produce
common behavioural phenotypes, which is consistent with the view
that autism can result from positive and negative changes in
neurotransmitter signalling (Zoghbi and Bear, 2012).
5HT neurons in the hindbrain are derived from progenitors
exposed to the signalling molecule sonic hedgehog (Shh) (Jessell,
2000). Serotonergic progenitor identity is characterised by
expression of the transcription factors Nkx2.2, Foxa2 and Ascl1, all
of which are required for 5HT neuronal differentiation (Briscoe et
al., 1999; Jacob et al., 2007; Pattyn et al., 2004). Newly born 5HT
neurons express post-mitotic determinants, including the
transcription factor Pet1 (Hendricks et al., 2003) and subsequently
the 5HT biosynthetic enzyme Tph2 (Zhang et al., 2004).
We investigated the molecular pathophysiology underlying
serotonergic deficits in a zebrafish FVS model because this could
provide mechanistic insight into the genesis of core autism
behaviours. Importantly, hindbrain development and neuronal
subtype diversity and serotonergic differentiation show strong
conservation (Lillesaar, 2011). Furthermore, zebrafish exposed to
VPA display morphological defects similar to those described in
FVS, suggesting the validity of our system for modelling features of
human FVS (Gurvich et al., 2005; Herrmann, 1993). We show that
VPA specifically blocks hindbrain 5HT expression in zebrafish.
Acting via Hdac1, VPA silences the zebrafish ortholog of
mammalian Ascl1, ascl1b, by unmasking tonic Notch repression.
Moreover, Ascl1b is sufficient to rescue 5HT expression in VPA-
treated embryos.
RESULTS
VPA impairs central 5HT neuronal differentiation
To assess the effect of VPA on brainstem development, we exposed
zebrafish gastrulae at 50% epiboly to 0.625 mM VPA until 27 hours
post-fertilisation (hpf), at which time the drug was removed and the
embryos were allowed to develop until 48 hpf. Treatment from
gastrulation was based on the heightened risk of teratogenicity in
human infants exposed to VPA during the first trimester of
pregnancy (Ornoy, 2009). Immunostaining for a range of hindbrain
neuronal subtypes, specifically motor neurons, 5HT neurons,
GABA-ergic neurons and Mauthner neurons, revealed a failure of
5HT neuronal differentiation marked by absence of 5HT expression
(Fig. 1A). Additionally, Mauthner neurons, which express a
neurofilament-associated antigen that is detected by the 3A10
monoclonal antibody, were also absent (Hatta, 1992; Schier et al.,
1996) (Fig. 1A). Isl1-positive motor neurons and GABA-ergic
neurons were present. The spatial distribution of motor neurons in
VPA-treated embryos appeared subtly altered, suggesting migratory
defects, but we did not pursue these changes further (Fig. 1A).
Instead we focused on the striking serotonergic phenotype.
We speculated that exposure to VPA from gastrulation could
affect common steps in the differentiation of multiple neuronal
lineages. Therefore, we treated embryos with 0.625 mM VPA from
24-48 hpf and used appropriate markers to detect brainstem neuronal
subtypes (Fig. 1B,C). Somatic motor, GABA-ergic and Mauthner
neurons were still present (Fig. 1C), but there was a specific deficit
of 5HT neuronal differentiation, marked by the absence of 5HT and
tph2 expression (Fig. 1B). Moreover, there was an absence or severe
reduction of pet1 expression, which indicates that VPA acts at a step
proximal to or at the early stages of 5HT neuronal differentiation
(Fig. 1B). Lower doses than this did not consistently lead to the loss
of 5HT expression (see supplementary material Fig. S1).
Having established that brainstem 5HT expression was
specifically lacking in embryos treated with VPA from 24 hpf, we
addressed whether there was a delay in the differentiation of 5HT
neurons. VPA was removed at 48 hours and embryos were analysed
after a further 24 hours of incubation (Fig. 1D). There was limited
recovery of 5HT expression at 72 hpf [mean number of 5HT
neurons in controls=26.7±1.7 (s.d.), n=3; mean number of 5HT
neurons in VPA-treated condition=1.8±1.3, n=4], which suggests
that VPA does not merely retard the differentiation of 5HT neurons.
We conclude that VPA specifically blocks the differentiation of 5HT
neurons in embryos exposed to the drug between 24 and 48 hpf.
This period coincides with the onset of differentiation of 5HT
neurons between 25 and 30 hpf (Lillesaar et al., 2007). Because the
post-mitotic differentiation of 5HT neurons is well underway from
48 hpf onwards (Lillesaar et al., 2007; McLean and Fetcho, 2004),
we asked whether VPA could abolish 5HT expression after 48 hpf.
VPA exposure between 48 hpf and 72 hpf had no effect on 5HT
expression (Fig. 1D) (mean number of 5HT neurons=25.8±2.5,
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TRANSLATIONAL IMPACT
Clinical issue
The drug valproate is used worldwide as an anticonvulsant agent, as a
mood stabiliser and for its pain-relieving properties. Valproate is
teratogenic (interferes with early development) and fetal exposure
causes fetal valproate syndrome (FVS), which is characterised by a
spectrum of morphological, cognitive and behavioural deficits. Recent
population-based epidemiological studies have highlighted the
significantly increased risk of autism spectrum disorders (ASDs) in
children exposed to valproate in utero. The in vivo mechanism of
valproate action that is pertinent to its neuropsychiatric side effects is not
clear. Multiple in vitro mechanisms have been described, including
inhibition of histone deacetylases. Studies on animal models of FVS
have identified biochemical and cellular perturbations of the central
serotonergic system. Altered serotonin homeostasis is also a feature of
idiopathic autism; therefore, uncovering the pathogenesis of serotonin
deficits in FVS could reveal the molecular underpinnings of core
behavioural abnormalities in autism. 
Results 
Zebrafish are highly suited to pharmacological and genetics approaches
that can be combined to provide novel insights into disease mechanisms.
In this article, the authors describe a zebrafish model of FVS that
displays a failure of serotonergic differentiation in the brainstem in
response to valproate treatment. They show that a critical proneural
gene, ascl1b, is silenced by valproate through a mechanism that
depends on inhibition of the histone deacetylase Hdac1. Their
experiments further show that valproate unmasks tonic repression of the
ascl1b gene by the Notch pathway. If the Notch pathway is blocked,
valproate is no longer able to silence ascl1b. Importantly, restoration of
Ascl1b in the presence of valproate rescues the expression of serotonin
in the zebrafish brainstem. 
Implications and future directions 
This study shows that valproate represses expression of ascl1b, leading
to defects in the serotonergic system in zebrafish. The failure in
serotonergic differentiation in this new model is reminiscent of defects
reported previously for mice exposed to valproate, suggesting that the
mechanism unveiled herein is likely to provide a common molecular
explanation for serotonergic abnormalities in this disorder. Indeed, the
conservation of the differentiation pathways of serotonergic neurons in
zebrafish and in humans suggests that these findings will be relevant to
understanding the complex pathophysiology of FVS. More broadly, the
authors highlight an epigenetic mechanism at work in an iatrogenic form
of ASD that could also be relevant to idiopathic, common forms of
autism.
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n=4). These data suggest that VPA acts on serotonergic progenitors,
rather than on post-mitotic neurons.
To test whether specific neuronal subtypes are vulnerable to VPA
application from 24 hpf because they only differentiate at or after 24
hpf, we extended the range of neuronal subtypes assayed. Cerebellar
Purkinje neurons begin to differentiate from 3 dpf and are marked
by expression of Parv7 (Bae et al., 2009). Wild-type embryos were
incubated in VPA for a prolonged period, from 24 hpf to 4.5 dpf (see
supplementary material Fig. S2). Immunostaining against Parv7
showed the persistence of this cell type in VPA-treated embryos
(supplementary material Fig. S2). The differential sensitivity of 5HT
and Purkinje neurons suggests that vulnerability to the effects of
VPA is not linked directly to the timing of neuronal differentiation.
Inhibition of Hdac1 by VPA accounts for the failure of 5HT
neuronal differentiation
Next, we sought to identify the molecular pathway targeted by VPA
in blocking 5HT neuronal differentiation. Previous studies have
shown both in vivo and in vitro that VPA is an inhibitor of HDACs
at therapeutic concentrations (Göttlicher et al., 2001; Gurvich et al.,
2005; Kook et al., 2003; Phiel et al., 2001; Tremolizzo et al., 2002;
Yildirim et al., 2003). To test the involvement of Hdac1, we used a
zebrafish hdac1 mutant line, hdac1s436, that was previously isolated
in a forward genetic screen (Noël et al., 2008). Immunostaining of
hdac1s436 mutants revealed a lack of 5HT expression in the
brainstem at 48 hpf (Fig. 2A). However, by 72 hpf there was a
partial recovery of 5HT neuronal differentiation (Fig. 2B) that was
more complete than in VPA-treated embryos at the same stage
(Fig. 1D, middle panel) [mean number of 5HT neurons in control
siblings (sibs)=31±2.5, n=4; mean number of 5HT neurons in
mutants=25.3±5.4, n=4]. Apart from a severe reduction in the
differentiation of somatic motor neurons, marked by Isl1 expression,
which has been reported previously (Cunliffe, 2004), other neuronal
subtypes, GABA-ergic and Mauthner neurons, appeared intact
(Fig. 2A).
To further test the involvement of HDACs in 5HT neuron
production, wild-type embryos were treated with the HDAC
inhibitor trichostatin A (TSA), a potent inhibitor of class I and class
II HDACs (Yoshida et al., 1990). Pharmacological blockade of
HDACs with TSA from 24-48 hpf recapitulated the effect of VPA
treatment, and resulted in loss of 5HT expression at 48 hpf, with
preservation of somatic motor, GABA-ergic and Mauthner cell
differentiation (Fig. 2A). This suggests that the hdac1s436 neuronal
phenotype differs from the effect of VPA most likely because of
differences in the timing of Hdac1 inactivation. Moreover, the
closely similar phenotypes that result from hdac1 mutation and VPA
treatment are consistent with the idea that VPA blocks 5HT neuronal
differentiation by inhibiting Hdac1.
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Fig. 1. Effect of valproate exposure on the differentiation of serotonergic and other brainstem neuronal subtypes. The timing of drug treatment is
indicated in this and all subsequent schematics by a coloured bar. Arrowheads mark the developmental stage of interest (hpf). Dashed lines with arrows indicate
the developmental time point at which embryos were harvested. (A) Immunostaining for brainstem neuronal subtypes in 48 hpf zebrafish embryos exposed to
VPA from 50% epiboly to 27 hpf [condition (i)] shows the failure of 5HT neuronal differentiation (n=22/22, P<0.0001), marked by 5HT (yellow arrowheads in
control panel), and lack of Mauthner neurons (n=22/22), marked by the 3A10 anti-neurofilament monoclonal antibody (yellow arrowheads in control panel). Isl1+
motor neurons (yellow arrowheads in control and VPA panels) (n=10/10) and GABA-ergic neurons (n=10/10) persist. Scale bar: 50 μm. (B) Failure of
serotonergic differentiation in embryos treated with VPA from 24-48 hpf [condition (ii)], as indicated by lack of 5HT (n=32/32, P<0.0001) and Tph2 expression.
Pet1 (arrowhead) is severely reduced (n=3/15) or absent (n=12/15) in VPA-treated embryos. (C) Persistence of Mauthner, motor and GABA-ergic neurons in
VPA treatment condition (ii). (D) At 72 hpf, embryos treated with VPA from 24-48 hpf [condition (iii)] show a limited recovery of 5HT expression (n=30/30).
Treatment with VPA from 48-72 hpf [condition (iv)] does not affect serotonergic differentiation (n=30/30). hpf, hours post-fertilisation. Scale bar: 50 μm.
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VPA downregulates expression of the proneural gene ascl1b
in serotonergic progenitors through a mechanism
consistent with Hdac1 inhibition
Next we examined the expression of transcription factors that specify
serotonergic progenitors. We reasoned that, because  5HT neurons are
absent, any disruption of serotonergic fate determinants might occur
before the first 5HT neurons are born. We therefore exposed 24 hpf
embryos to VPA and analysed gene expression by in situ hybridisation
8 hours later. There was a striking reduction of ascl1b expression by
32 hpf that was not apparent at 28 hpf, just 4 hours earlier (Fig. 2C).
Colocalisation of ascl1b and nkx2.2 in the hindbrain by fluorescent
double in situ hybridisation confirmed the expression of ascl1b in
serotonergic progenitors (Fig. 2D). Expression of the related gene
ascl1a and other fate determinants, nkx2.2 and foxa2, and the
signalling molecule shh were unchanged, which implies that the loss
of ascl1b expression is not due to depletion of progenitors (Fig. 2E).
Further evidence implicating Hdac1 as the mediator of the effects
of VPA on 5HT neurons is that, in hdac1s436 mutants, expression of
ascl1b is also severely reduced, a finding that has been reported
previously in a different hdac1-null mutant line (Fig. 2C) (Cunliffe,
2004).
In contrast to the downregulation of ascl1b, another bHLH
proneural gene, ptf1a, which is required for the generation of
cerebellar Purkinje neurons (Hori et al., 2008), was not decreased
by VPA. Ptf1a expression in the cerebellar primordium is first
detected at 48 hpf (Kani et al., 2010). We monitored ptf1a
expression by in situ hybridisation for ptf1a transcripts in wild-type
zebrafish embryos and by an eGFP reporter in a transgenic ptf1a-
egfp line at 52 hpf in embryos continuously exposed to VPA from
24 hpf (see supplementary material Fig. S2) (Pisharath et al., 2007).
The persistent ptf1a expression suggests that proneural genes are
differentially sensitive to VPA and this is consistent with the
continued differentiation of Purkinje neurons after VPA exposure
(see supplementary material Fig. S2).
Notch signalling represses ascl1b in the presence of VPA
VPA has previously been reported to upregulate Notch signalling in
a variety of systems (Greenblatt et al., 2007; Stockhausen et al.,
2005). In zebrafish embryos this effect seems likely to be mediated
by Hdac1 (Cunliffe, 2004). One possibility, therefore, was that
Hdac1 was inhibiting the Notch pathway and thus decreasing the
Notch-mediated inhibition of ascl1b via Her genes, which are the
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Fig. 2. Failure of serotonergic differentiation in VPA-treated embryos is mimicked by blockade of Hdac1 activity and is associated with
downregulation of ascl1b. (A) hdac1 mutation or pharmacological blockade mimics the effect of VPA on the differentiation of brainstem neuronal subtypes. At
48 hpf, hdac1s436 mutants lack 5HT neurons (n=15/15, P<0.0001) and show a severe depletion of Isl1+ motor neurons. Treatment with TSA from 24 to 48 hpf
[condition (vii)] selectively affects 5HT expression (n=30/30, P<0.0001), but other neuronal subtypes are retained. Scale bar: 50 μm. (B) Partial recovery of 5HT
neuronal differentiation in hdac1s436 mutants at 72 hpf (n=14/14). Scale bar: 50 μm. (C) Short duration (8 hour) exposure to VPA from 24 hpf [condition (vi)]
leads to the downregulation of ascl1b expression (n=15/15), and similar loss of ascl1b expression is observed in hdac1s436 mutants (n=10/10). Rhombomeres
(r) marked by arrowheads. Scale bar: 50 μm. (D) Double in situ hybridisation showing ascl1b expression in serotonergic progenitors, marked by expression of
nkx2.2. Co-labelled cells are indicated by white arrowheads. Scale bar: 20 μm. (E) Short-duration VPA treatment [condition (viii)] does not affect the expression
of the paralogous gene ascl1a, or other progenitor-expressed determinants of serotonergic fate, nkx2.2, foxa2 or shh (arrowheads).
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major effectors of Notch signalling in zebrafish (Cunliffe, 2004;
Louvi and Artavanis-Tsakonas, 2006). A second possible
mechanism is through direct upregulation of ascl1b by Hdac1
(Cunliffe, 2004; Harrison et al., 2011; Wang et al., 2009). Finally,
Hdac1 repression of specific members of the Her family, in
particular her6, which in turn represses ascl1b, is a third possibility
(Cunliffe, 2004; Harrison et al., 2011).
her4 is a direct target of Notch signalling that is widely used as a
readout of Notch activity (Takke and Campos-Ortega, 1999; Takke
et al., 1999; Yeo et al., 2007). The downregulation of ascl1b in
embryos following an 8-hour treatment with VPA from 24 hpf
(Fig. 2C) was not accompanied by obvious elevation of her4
expression (Fig. 3A,B). Quantitative reverse-transcriptase PCR
confirmed that there was a modest decrease in her4 expression
relative to untreated control embryos (Fig. 3A). her6 is also a target
of the Notch pathway and to date is the only Her gene reported to
undergo negative regulation by Hdac1 (Cunliffe, 2004). In situ
hybridisation for her6 and a panel of additional Her family members
in wild-type embryos similarly treated with VPA also showed no
difference in expression compared with controls (data not shown).
To investigate the involvement of the Notch pathway in ascl1b
repression by VPA, we inhibited Notch signalling over the same
period and determined whether VPA could still repress ascl1b.
Embryos at 22 hpf were treated with a small-molecule inhibitor of
Notch signalling, the γ-secretase inhibitor DAPT, which is known
to have potent activity in vivo in zebrafish (Geling et al., 2002;
Imbimbo, 2008). DAPT treatment alone from 22-32 hpf effectively
downregulated her4 expression, whereas ascl1b expression was
maintained (Fig. 3A,C). Strikingly, following the addition of VPA at
24 hpf, her4 remained repressed and ascl1b expression persisted
(Fig. 3A,C). Therefore, the repression of ascl1b by short-term
exposure to VPA is prevented by concomitant blockade of Notch
signalling, which implies that a basal level of Notch signalling
represses ascl1b when Hdac1 activity is blocked.
To confirm that the repression of Ascl1b by VPA is not due to
increased Notch signalling secondary to blockade of Hdac1
function, we analysed her4 expression in hdac1s436 mutants at 32 hpf
(Fig. 3B). There was a marked reduction of her4 expression in
mutant hindbrains, indicative of reduced Notch signalling (Fig. 3B).
Therefore, VPA inhibition of Hdac1 does not repress ascl1b through
the upregulation of Notch signalling, or via Hdac1-mediated
repression of her4 or her6. Instead, Hdac1 acts independently of
Notch activity to regulate ascl1b. Moreover, a parallel, tonic level
of Notch signalling was sufficient to repress ascl1b transcription
when Hdac1 was inhibited by VPA.
Hdac1 and Notch have opposing effects on ascl1b
To confirm the parallel roles for Hdac1 and Notch signalling, we
tested whether DAPT could restore ascl1b expression in hdac1s436
mutants. hdac1s436 mutants and sibs were treated with DAPT from
22 hpf (Fig. 4A). At 32 hpf, sibs treated with DAPT showed strong
expression of ascl1b, which was virtually absent by 48 hpf
presumably because of depletion of the progenitor pool caused by
the blockade of Notch signalling. Remarkably, DAPT restored
ascl1b expression in hdac1s436 mutants, and expression was
maintained at least up to 48 hpf (compare Fig. 2C and Fig. 4A). The
other progenitor markers, nkx2.2, foxa2 and shh, were not altered by
DAPT in either sibs or hdac1s436 embryos at 48 hpf (Fig. 4B). These
data confirm that Hdac1 and Notch exert positive and negative
regulatory effects, respectively, on ascl1b. Given the finding that
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Fig. 3. VPA treatment exposes cryptic transcriptional repression of
ascl1b by basal levels of Notch signalling. (A) Quantitative reverse-
transcriptase PCR showing that VPA mildly reduces her4 expression,
whereas DAPT strongly reduces her4 expression to between 12% and
23% of control levels (*P=0.017, **P=0.001). (B) Short duration (8 hour)
treatment with VPA [condition (viii)] does not upregulate her4 expression
at 32 hpf (n=12/12). Downregulation of her4 expression in hdac1s436
mutant hindbrain at 32 hpf (n=5/5). Scale bar: 50 μm. (C) Concomitant
blockade of Notch signalling using the γ-secretase inhibitor DAPT
prevents the downregulation of ascl1b by VPA. Loss of her4 expression
in DAPT-treated embryos [conditions (ix) and (x)] (upper panels)
(n=35/35). Persistence of ascl1b expression in embryos treated with
VPA and DAPT [condition (x)] (n=23/23).
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DAPT could prevent the repression of ascl1b by VPA, the
expression of ascl1b was then analysed in a Notch-signalling
mutant, mindbomb (mib). These mutants lack an E3 ubiquitin ligase,
which is crucial for Notch signalling (Itoh et al., 2003; Schier et al.,
1996). Consistent with the data from chemical inhibition of Notch
signalling, the expression of ascl1b was restored in 32 hpf mib
mutants treated with VPA from 50% epiboly to 27 hpf (Fig. 4C).
Failure of 5HT neuronal differentiation in VPA-treated
embryos is due to repression of ascl1b
Finally, we asked whether replacement of ascl1b was sufficient to
rescue 5HT neuronal differentiation in VPA-treated embryos. To test
this, a plasmid encoding a Myc-tagged full-length Ascl1b (ascl1b-
myc) under the control of UAS was injected into a stable transgenic
zebrafish line, ubi:ERT2-GAL4 (Gerety et al., 2013), which allows
the regulation of ascl1b-myc by 4-hydroxytamoxifen (4-OHT). In
control embryos treated with VPA alone, Ascl1b-Myc could not be
detected by immunostaining for Myc antigen (Fig. 5A) and 5HT-
expressing neurons were absent. Addition of 4-OHT resulted in
strong and widespread expression of Ascl1b-Myc and the rescue of
5HT neuronal differentiation in 16% of embryos (Fig. 5A,
P=0.0058).
If repression of ascl1b is the reason for the failure of 5HT
neuronal differentiation upon VPA exposure, then restoration of
ascl1b expression in hdac1s436 and mib mutants should be sufficient
to rescue 5HT expression. Indeed, immunostaining of DAPT-treated
hdac1s436 embryos at 48 hpf revealed the rescue of 5HT expression
in the raphe (Fig. 5B). We also exposed mib mutants to VPA from
gastrulation (50% epiboly) to 27 hpf, and then incubated the
embryos in normal medium until 48 hpf, at which time they were
fixed and immunostained for 5HT. We had already established that
an identical VPA regime abolishes 5HT expression on a wild-type
background (Fig. 1A). Untreated mib mutants lacked 5HT neurons
but, remarkably, 5HT neurons were generated in mib mutant
embryos exposed to VPA (Fig. 5C). These findings confirmed that
the loss of 5HT expression in VPA-treated embryos was not due to
neuronal death, but instead was due to a block in their
differentiation.
DISCUSSION
Using a zebrafish model of FVS, we have identified a molecular
mechanism to explain the loss of 5HT neurons, which have been
implicated in the neuropsychiatric manifestations of FVS. Two
different VPA treatment regimes caused the failure of serotonergic
differentiation, and the late-dosing regime (24-48 hpf) seemed to
have greater selectivity for the serotonergic system than the early-
dosing schedule (50% epiboly to 27 hpf). There is wide variation in
the teratogenic dose of VPA in human and animal studies
(Christensen et al., 2013; Ornoy, 2009), which makes direct
comparisons of dosing regimes between different model organisms
and with humans exposed to VPA in utero difficult to interpret.
Nevertheless, the altered serotonergic differentiation in this zebrafish
model is reminiscent of similar deficits that are found in rodent
models, which correlate with autism-like behavioural abnormalities
(Dufour-Rainfray et al., 2010; Dufour-Rainfray et al., 2011).
Recovery of ascl1b expression in VPA-treated hdac1s436 or mib
mutant embryos is associated with rescue of 5HT neuronal
differentiation. However, direct replacement of Ascl1b is sufficient
to rescue 5HT expression in only 16% of embryos. Suboptimal
timing or level of the ectopically expressed Ascl1b expression might
explain the lower efficiency. Alternatively, non-physiological,
persistent high-level expression of Ascl1b in post-mitotic neurons
might account for the low rate of rescue (Cai et al., 2000).
Nevertheless, taken together these findings indicate that the failure
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Fig. 4. Ascl1b transcriptional regulation by opposing
Hdac1 and Notch activities. (A) Blockade of Notch
signalling by DAPT in hdac1s436 mutants [condition (xi)]
results in the recovery of ascl1b expression at 32 hpf and
48 hpf (arrowheads) (n=15/15 for both developmental
stages combined). Arrowheads indicate the expression
domain of ascl1b. (B) DAPT treatment of hdac1s436
mutants [condition (xi)] does not affect the expression of
nkx2.2 (n=7/7), foxa2 (n=8/8) and shh (n=6/6)
(arrowheads) at 48 hpf. Arrowheads indicate the
expression domain of the respective genes in the ventral
midline of the embryo. Scale bar: 50 μm. (C) VPA
treatment of embryos on the Notch signalling mutant
mindbomb (mib) background [condition (i)] is associated
with recovery of ascl1b expression (n=11/11). (D) Model
of transcriptional regulation of ascl1b by Hdac1 and the
Notch pathway. Solid arrows indicate direct positive
regulation. Lines with an orthogonal bar represent
inhibition. The inhibitory arrow with a question mark above
it, from Hdac1 to Her, takes account of the possibility that
another Her gene (or another transcription factor of
unknown identity) that represses ascl1b is in turn
repressed by Hdac1.
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of 5HT neuronal differentiation in our model of FVS is most
probably due to the loss of ascl1b expression. We cannot, however,
exclude the possibility that VPA disrupts the expression of other,
unknown, genes that are crucial for 5HT neuronal differentiation.
We anticipate that the finding of downregulated expression of ascl1b
in our zebrafish model will prompt closer analysis of rodent FVS
models for changes in the expression of the mammalian ortholog
Ascl1 in serotonergic progenitors. Ascl1 is known to be required for
neuronal-subtype specification, which is separable from its better-
known proneural function (Goridis and Brunet, 1999). In mammals,
a requirement for Ascl1 in serotonergic differentiation has previously
been demonstrated, including for the expression of 5HT itself, and
this subtype-specification function cannot be substituted by other
proneural genes (Jacob et al., 2009; Parras et al., 2002; Pattyn et al.,
2004). Additionally, Ascl1 has been shown to be essential for the
acquisition of noradrenergic traits in all mammalian central and
peripheral neurons (Blaugrund et al., 1996; Guillemot et al., 1993;
Hirsch et al., 1998). At least in part, Ascl1 regulates neurotransmitter
phenotype in noradrenergic neurons in collaboration with Phox2
genes (Pattyn et al., 2000). However, Phox2 genes are not expressed
in the mammalian serotonergic lineage. Instead, Ascl1 regulation of
the zinc-finger transcription-factor-encoding gene Insm1 in post-
mitotic serotonergic precursors is a crucial component of the
mammalian serotonergic transcriptional programme (Jacob et al.,
2009).
Using the HDAC inhibitor TSA and an hdac1 mutant line, we
have provided evidence that the effect of VPA on serotonergic
differentiation is mediated through Hdac1 inhibition. These findings
are consistent with previous reports that VPA inhibits HDACs in
vivo (Gurvich et al., 2005). Moreover, Hdac1 is one of the key
molecular factors that regulate the transcription of ascl1b and these
data are consistent with the previously identified positive regulatory
role of Hdac1 (Cunliffe, 2004; Harrison et al., 2011). The regulation
of ascl1b might be direct given that Hdac1 binds to the ascl1b
promoter (Harrison et al., 2011). It has been proposed that Hdac1
promotes activation of ascl1b directly by participating in cycles of
deacetylation and histone-acetyltransferase-dependent acetylation of
transcription-unit-associated histones, and/or by maintaining the
ascl1b promoter in a transcriptionally poised state (Wang et al.,
2009). Nevertheless, we do not rule out the possibility that Hdac1
functions indirectly by inhibiting the expression of a transcriptional
repressor of ascl1b (Fig. 4D).
A second transcriptional regulator of ascl1b that is unmasked by
VPA is repressive regulation by the Notch pathway. It was shown
previously that VPA upregulates Notch signalling and this is
associated with increased expression of Notch effector genes
(Greenblatt et al., 2007; Stockhausen et al., 2005). Therefore, we
expected that repression of ascl1b by VPA might be mediated by
enhanced Notch signalling. However, short-duration VPA treatment
is sufficient to downregulate ascl1b without concomitantly
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Fig. 5. Ascl1b is sufficient to rescue serotonergic differentiation in VPA-treated embryos. (A) Mis-expression of Myc-tagged Ascl1b in VPA-treated
transgenic embryos rescues 5HT neuronal differentiation. A stable transgenic line expressing ERT2-GAL4 under the control of the ubiquitin (ubi) promoter was
injected at the one-cell stage with plasmid DNA encoding Ascl1b-Myc under the control of UAS. Embryos were treated with VPA with or without 4-
hydroxytamoxifen (4-OHT) [condition (xii)]. Myc immunostaining in shown in green. The upper and lower left panels show low-power views (scale bar: 500 μm)
of Myc-immunostained zebrafish embryos treated with VPA in the absence (upper panel) or presence (lower panel) of 4-OHT. Addition of 4-OHT leads to
widespread expression of Ascl1b-Myc (bottom left panel). Panels to the right show high-power views (scale bar: 50 μm) of Myc (green) and 5HT (red)
immunostaining in the hindbrain of transgenic embryos. Embryos treated with VPA alone fail to express 5HT (n=51/51). Addition of 4-OHT and induction of
Ascl1b-Myc expression rescues 5HT expression in 8/51 VPA-treated embryos (P=0.0058). Upper right and bottom right panels are high-power (scale bar: 20
μm) views of the boxed areas in the panels immediately to the left. The bottom, middle panel inset shows a higher-power view of the 5HT-expressing cells in
the boxed area. The bottom right panel shows merged channels representing Ascl1b-Myc (green) and 5HT (red) immunostaining. (B) In hdac1s436 mutants
treated with DAPT [condition (xi)], there is a rescue of 5HT neuronal differentiation at 48 hpf (n=22/22, P<0.0001). Scale bar: 50 μm. (C) On the mib mutant
background there is a recovery of 5HT neurons at 48 hpf in VPA-treated embryos [condition (i)] (n=12/12, P=0.0002). Inset shows a high-power image of the
boxed region.
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enhancing Notch signalling. Consistent with this, the expression of
a panel of Her genes, including her4, a target of Notch signalling,
and her6, are not appreciably altered under these conditions.
Nevertheless, our findings using chemical and genetic blockade of
Notch function demonstrate that parallel Notch signalling
participates in the VPA-mediated downregulation of ascl1b
(Fig. 4D). Importantly, only a basal level of Notch signalling is
required for VPA downregulation of ascl1b. Together, our findings
lead to a revised view of ascl1b regulation based on a derepression
model, because removal of the basal inhibitory Notch input when
Hdac1 function is blocked by VPA is sufficient for ascl1b
transcription.
The regulatory relationship between Hdac1 and the Notch
pathway in the control of ascl1b expression reported in a previous
study (Cunliffe, 2004) provided an opportunity to evaluate further
whether VPA blockade of serotonergic differentiation occurs via
Hdac1 inhibition. In hdac1 mutants, we found that her4 expression
is reduced (Fig. 3B). Our result differs from the latter study that
proposed increased Notch signalling in hdac1 mutants based on
enhanced her6 expression (Cunliffe, 2004). A possible explanation
for the difference is that her6 expression in hdac1 mutants is
developmental-stage-dependent. The loss of ascl1b expression in
hdac1s436 mutants and in VPA-treated embryos (Fig. 2C) occurs in
the absence of enhanced Notch pathway activity during the period
of treatment. This is consistent with Hdac1 inhibition as the salient
in vivo mechanism of VPA. Moreover, these data are also consistent
with direct regulation of ascl1b by Hdac1.
Because VPA has been reported to have a variety of modes of
action, identifying which of these mechanisms is relevant in vivo
for the behavioural manifestations of FVS is challenging. This is
an important question, however, because identification of the
molecular mechanism has potential therapeutic significance. The
involvement of Hdac1 in the serotonergic deficit in FVS strongly
suggests that an epigenetic mode of action could mediate at least
some of the behavioural manifestations of FVS. This is not an
isolated finding, because epigenetic contributions to other ASDs
have been noted. Methyl-CpG-binding protein 2 (MECP2), which
is implicated as the cause of the ASD-associated disease Rett
syndrome contains a transcriptional repression domain, which
physically interacts with the transcriptional co-repressor Sin3A
(Amir et al., 1999). In turn, Sin3A recruits HDAC1 and HDAC2,
which are believed to mediate transcriptional repression by
MECP2 (Jones et al., 1998; Nan et al., 1998). More broadly,
epigenetic modifications seem to regulate autism susceptibility; for
example, autism is associated with duplications of 15q11-13,
which is an imprinted region of the genome where DNA
methylation status is associated with Prader-Willi syndrome and
Angelman syndrome (Dykens et al., 2011). In conclusion,
epigenetic regulation of gene expression seems to be an emerging
point of convergence for environmental agents and hereditary
factors in ASD pathogenesis.
MATERIALS AND METHODS
Zebrafish strains and husbandry
Zebrafish embryos were staged according to hpf and morphological criteria
(Kimmel et al., 1995). mib mutant embryos were obtained by incrosses of
heterozygote mib zebrafish. They were identified by the irregular appearance
of the hindbrain, markedly reduced hindbrain ventricle and loss of early
somite boundaries (Stickney et al., 2000; van Eeden et al., 1996). hdac1s436
mutants were generated by incrosses of heterozygote hdac1s436 zebrafish
(Noël et al., 2008). Mutants were identified by their smaller CNS, narrow
anterior rhombomeres, reduced midbrain ventricle, cleft eyes, retinal
hypopigmentation, curled shape and, at 48 hpf, additionally by absent
pectoral fins (Cunliffe, 2004). ubi:ERT2-GAL4 transgenic zebrafish were
generated as described (Gerety et al., 2013).
Transgenic constructs and transient transgenic zebrafish
DNA encoding Ascl1b tagged with six copies of Myc at the C-terminus was
made by gene synthesis (Genwiz). ascl1b-myc was subcloned into a 5× UAS
plasmid containing a miniTOL2 backbone to facilitate genomic integration
in zebrafish (Balciunas et al., 2006). Transient transgenic embryos were
generated by co-injecting 10-20 pg of UAS:ascl1b-myc plasmid DNA with
25 pg of tol2 transposase mRNA into one-cell-stage embryos obtained by
intercrossing UBI:ERT2-GAL4 transgenic zebrafish.
Reverse transcriptase PCR (RT-PCR) and primer sequences
Between 30 and 40 embryos at 32 hpf were used for each condition and
experiments were performed in triplicate. At the end of the period of drug
treatment embryos were placed in Trizol, homogenised, chloroform was
added, the sample was centrifuged at 4°C, glycogen and isopropanol were
added, the sample was then centrifuged again at 4°C, 75% ethanol was
added, centrifugation at 4°C was repeated and the pellet was re-suspended
in water. RNA purification was performed using the RNeasy Micro Kit
(Qiagen) according to the manufacturer’s instructions. cDNA synthesis was
performed using the Superscript First-Strand Synthesis System for RT-PCR
(Invitrogen), according to the manufacturer’s instructions. Quantitative RT-
PCR was performed using the 7900HT Fast Real-Time PCR System
(Applied Biosystems).
The following primers were used for RT-PCR: her4 5′-
AGCAGCAGCCCGACTCCAGA-3′, 5′-GCTGACGGCCTCCTGCACAC-
3′; beta-actin2 5′-CGAGCTGTCTTCCCATCCA-3′, 5′-TCACCAACGT -
AGCTGTCTTTCTG-3′. Data was analysed using the Student’s t-test.
Immunohistochemistry and in situ hybridisation
For immunofluorescence and in situ hybridisation, embryos were fixed in
4% paraformaldehyde (PFA) either for 2-3 hours at room temperature or
overnight at 4°C. For immunofluorescence, embryos were rinsed three times
in 0.1% Tween in phosphate buffered saline (PBST), incubated for 20
minutes in 0.01 mg/ml proteinase K (Roche) in PBST/0.2% BSA/2% heat-
inactivated goat serum solution (PBT), post-fixed in PFA, washed three
times in PBT, blocked in PBT containing 1% DMSO, 0.5% Triton-X and
1% BSA (PBDT), and then incubated for 24 hours at 4°C in primary
antibody in PBST. The following day, embryos were washed four times in
PBT, blocked again in PBDT and then incubated in secondary antibody
overnight in PBDT. Further washes in PBT were performed the next day,
and embryos were then transferred to 70% glycerol and mounted under
coverslips for viewing. Immunofluorescence staining was visualised by
confocal microscopy (Leica TCS SP2). For single and double in situ
hybridisation, embryos were processed as described (Lauter et al., 2011).
Fluorescent signals were developed with Fast Blue and Fast Red.
Differences between embryos were analysed using Fisher’s exact test.
The following antibodies were used: rabbit anti-5HT (1/500, Millipore),
rabbit anti-GABA (1/500, Sigma), 3A10 mouse anti-neurofilament (1/25,
DSHB), mouse anti-Parvalbumin7 (1/1000, gift from Dr Masahiko Hibi,
Nagoya University, Japan), 4D5 mouse anti-Isl1 (1/45, DSHB), mouse anti-
myc (1/500, Santa Cruz). The following riboprobes were used: foxa2
(Strähle et al., 1993), nkx2.2 (Barth and Wilson, 1995), shh (Krauss et al.,
1993), her4 (Takke et al., 1999), her6, tph2 (also called tphR) (Teraoka et
al., 2004), ascl1a, ascl1b (Allende and Weinberg, 1994), ptf1a (Zecchin et
al., 2004). pet1 (IMAGE ID: 7000463) was subcloned from p-Express1 into
pBluescript, then linearised with EcoRI (Roche) and transcribed using T7
Polymerase (Promega).
Drugs
Embryos were dechorionated manually prior to drug treatment. Sodium
valproate (Sigma) was dissolved in water as a 2 M stock solution and was
used at a final concentration of 0.625 mM. This dose is comparable to doses
found to inhibit HDACs in vivo in other studies (Gurvich et al., 2005).
Lower doses did not consistently abolish 5HT expression in the hindbrain
(see supplementary material Fig. S1). DAPT (Calbiochem) was dissolved in
RESEARCH ARTICLE Disease Models & Mechanisms (2014) doi:10.1242/dmm.013219
D
is
ea
se
 M
od
el
s 
&
 M
ec
ha
ni
sm
s
DMSO as a 46 mM stock solution and used at 200 μM final concentration,
which is similar to doses previously reported to block Notch signalling in
zebrafish (Geling et al., 2002). A 5 mM TSA solution in DMSO (Sigma)
was diluted to a final concentration of 2 μM in fish water prior to use, which
is comparable to doses used in vivo to inhibit HDACs (Gurvich et al., 2005).
4-OHT (Sigma) was dissolved in ethanol at 12.5 mg/ml. Dilutions of 4-OHT
were made to 1.5 μM in standard fish water just prior to use. In all drug
conditions, controls were treated with an equivalent amount of vehicle
diluted in fish water. Stock solutions of all these drugs were stored at −20°C.
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